To continue reading and help Philly news thrive, unlock this exclusive offer for unlimited digital access to Inquirer.com and ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022.

Michael Botta is co-founder and president of Sesame, a health-care marketplace.

The first patient has been enrolled in a trial evaluating ClarityDX Prostate’s impact on early prostate cancer detection, ...

Liquid biopsy is a revolutionary molecular diagnostic tool that allows scientists to detect genetic abnormalities or monitor disease progression non-invasively. However, clinicians encounter several ...

For men at the highest risk of prostate cancer as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been ...

The minimally invasive approach has already been successfully tested in animals as a biopsy tool for tumours, though they can also deliver molecules, implant electrodes and collect data samples.

Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the ...

According to a recent report by Future Market Insights (FMI), the global biopsy device market is on a steady growth path, fueled by rising demand for early diagnostic tools and technological ...

Attard gets liquid biopsy samples for his research from prostate ... “It could be a great tool in the clinic.” Methylation-based assays such as the ones Proudhon and Attard are working on ...